In fact, many preclinical and clinical studies of pharmacological autophagy inhibitors were shown to enhance tumor cell death in combination with radiotherapy, chemotherapy, and other frequently employed molecular targeted agents in breast cancer, including CDK4/6i, PI3Ki, and AKTi.87,88 Importantly, we observed strong autophagy induction in therapy-naïve BC cells following metabolic drug treatment with Metformin or DCA, suggesting that the efficacy of Alpelisib could be compromised when directly combined with metabolic drug treatment. Here, CDK4 is linked to neoplasm.